.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Dow
Fuji
Cantor Fitzgerald
Merck
AstraZeneca
Farmers Insurance
McKesson
Deloitte
Chinese Patent Office

Generated: July 26, 2017

DrugPatentWatch Database Preview

Eprosartan mesylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for eprosartan mesylate and what is the scope of eprosartan mesylate patent protection?

Eprosartan mesylate
is the generic ingredient in three branded drugs marketed by Mylan Pharms Inc and Abbvie, and is included in three NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for eprosartan mesylate. One supplier is listed for this compound.

Summary for Generic Name: eprosartan mesylate

Tradenames:3
Patents:1
Applicants:2
NDAs:3
Drug Master File Entries: see list11
Suppliers / Packagers: see list1
Bulk Api Vendors: see list42
Clinical Trials: see list515
Patent Applications: see list1,280
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:eprosartan mesylate at DailyMed

Pharmacology for Ingredient: eprosartan mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-002Nov 1, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-006May 27, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
EPROSARTAN MESYLATE
eprosartan mesylate
TABLET;ORAL202012-002Nov 16, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-004Dec 22, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-005Dec 22, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: eprosartan mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-006May 27, 1999► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-004Dec 22, 1997► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-005Dec 22, 1997► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-006May 27, 1999► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-005Dec 22, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Fuji
QuintilesIMS
McKinsey
Novartis
Medtronic
Merck
UBS
Accenture
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot